首都医药
首都醫藥
수도의약
CAPITAL MEDICINE
2014年
16期
26-27
,共2页
刘学永%陈峰%王宏%李静华
劉學永%陳峰%王宏%李靜華
류학영%진봉%왕굉%리정화
胰激肽原酶%穴位注射%慢性肾小球肾炎%蛋白尿
胰激肽原酶%穴位註射%慢性腎小毬腎炎%蛋白尿
이격태원매%혈위주사%만성신소구신염%단백뇨
Pancreatic kallikrein%Acupoint injection%Chronic glomerulonephritis%Proteinuria
目的:探讨胰激肽原酶穴位注射对以蛋白尿为主的慢性肾小球肾炎的临床应用效果。方法将150例慢性肾小球肾炎患者随机分为对照组74例与治疗组76例,对照组采用常规药物治疗,治疗组在此基础上加用胰激肽原酶穴位注射治疗,观察两组患者24h蛋白水平及各项指标情况。结果治疗组患者总有效率88.15%,显著高于对照组的74.32%,且治疗组SCr、BUN、血β2微球蛋白水平显著优于对照组,以上指标与对照组比较差异有统计学意义(P<0.05)。结论穴位注射胰激肽原酶可有效控制慢性肾炎患者蛋白尿水平,该法简单易行,无毒副作用,值得在临床广泛推广应用。
目的:探討胰激肽原酶穴位註射對以蛋白尿為主的慢性腎小毬腎炎的臨床應用效果。方法將150例慢性腎小毬腎炎患者隨機分為對照組74例與治療組76例,對照組採用常規藥物治療,治療組在此基礎上加用胰激肽原酶穴位註射治療,觀察兩組患者24h蛋白水平及各項指標情況。結果治療組患者總有效率88.15%,顯著高于對照組的74.32%,且治療組SCr、BUN、血β2微毬蛋白水平顯著優于對照組,以上指標與對照組比較差異有統計學意義(P<0.05)。結論穴位註射胰激肽原酶可有效控製慢性腎炎患者蛋白尿水平,該法簡單易行,無毒副作用,值得在臨床廣汎推廣應用。
목적:탐토이격태원매혈위주사대이단백뇨위주적만성신소구신염적림상응용효과。방법장150례만성신소구신염환자수궤분위대조조74례여치료조76례,대조조채용상규약물치료,치료조재차기출상가용이격태원매혈위주사치료,관찰량조환자24h단백수평급각항지표정황。결과치료조환자총유효솔88.15%,현저고우대조조적74.32%,차치료조SCr、BUN、혈β2미구단백수평현저우우대조조,이상지표여대조조비교차이유통계학의의(P<0.05)。결론혈위주사이격태원매가유효공제만성신염환자단백뇨수평,해법간단역행,무독부작용,치득재림상엄범추엄응용。
Objective To investigate the clinical effect of treating chronic glomerulonephritis with proteinuria by pancreatic kallikrein point injection. Methods 150 cases of chronic glomerulonephritis patients were randomly divided into control group(74 cases)and treatment group(76 cases).The control group were taking conventional drug therapy, on the basement of it, the treatment group adding pancreatic kallikrein point injection therapy, observing 24h protein levels and various indicators. Results The total effective rate of treatment group was 88.15%,which was significantly higher than the control group (74.32 %), and the SCr, BUN, serum β2-microglobulin levels of the treatment group were significantly better than the control group, the difference was statistically significant (P<0.05). Conclusion The point injection pancreatic kallikrein can effectively control the proteinuria level of chronic nephritis patients, it's simple, non-toxic side effects, and widely used in clinical application.